No­var­tis ap­points Dr John Tsai as Head GDD, CMO

BioSpectrum (Asia) - - PEOPLE NEWS -

No­var­tis has an­nounced the ap­point­ment of John Tsai,

M.D. as Head of Global Drug Devel­op­ment (GDD) and Chief Med­i­cal Of­fi­cer. Dr Tsai will be based in Basel, Switzer­land. He will re­port to Dr Vas Narasimhan, M.D., CEO of No­var­tis and will be­come a mem­ber of the Ex­ec­u­tive Com­mit­tee of No­var­tis (ECN). Dr Tsai suc­ceeds Dr Narasimhan who be­came CEO of No­var­tis on Fe­bru­ary 1, 2018. Dr Rob Kowal­ski, who led GDD as in­terim since Fe­bru­ary 1, 2018, will re­sume his re­spon­si­bil­i­ties as Head of Global Reg­u­la­tory Af­fairs for GDD. Dr Tsai has been Chief Med­i­cal Of­fi­cer and Se­nior Vice Pres­i­dent of Global Med­i­cal at Am­gen Inc., since May 2017 and over­sees all clinical and med­i­cal func­tions across mul­ti­ple sites world­wide.

At No­var­tis, he will be re­spon­si­ble for ad­vanc­ing the com­pany’s in­dus­try-lead­ing pipe­line of in­no­va­tive medicines and biosim­i­lars. Dr Tsai will also lead the GDD or­ga­ni­za­tion’s on­go­ing trans­for­ma­tion em­brac­ing the power of ad­vanced data sciences and dig­i­tal tech­nolo­gies to cre­ate a more ag­ile model for drug devel­op­ment. Prior to join­ing Am­gen, Dr Tsai spent 11 years with Bris­tol-My­ers Squibb (BMS), where he served as Global Head of Clinical Devel­op­ment for mar­keted prod­ucts and global clinical oper­a­tions.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.